SANTA CLARA, Calif., Oct. 13 /PRNewswire/ -- Applied Imaging Corp.
(Nasdaq: AICX), today announced the signing of a multi-year distribution
agreement for cytogenetic instruments with Tokyo based Aloka Ltd., a leading
supplier of medical equipment in Japan. Aloka manufactures, markets,
distributes and services a wide range of products including systems for
medical ultrasound, bone densitometry, automated pipetting as well as
analytical instruments for molecular biology and genetic research including
DNA sequencers and automated DNA probe testing systems that complement Applied
Imaging's cytogenetic analysis systems.
"The Japanese market represents a tremendous opportunity for Applied
Imaging, and we are delighted to have partnered with an organization with
expertise in sales and service in the field of genetics," said Jack Goldstein,
Chairman and CEO of Applied Imaging. "As the exclusive distributor of our
cytogenetic analysis systems, we believe that Aloka, through the use of
dedicated resources, will significantly contribute to the future top line
growth of Applied Imaging."
About Aloka
Aloka Co., Ltd., is one of the Japan's leading developers, manufacturers,
and marketers of innovative medical equipment with annual sales of
approximately $360 million. With over forty years of experience Aloka is the
world's oldest ultrasound manufacturer and today has products that are
distributed on six continents. Aloka is committed to providing the technology
and products for the diagnosis and care of people around the world.
About Applied Imaging, Corp.
Applied Imaging Corporation, based in Santa Clara, Calif., develops,
manufactures, and markets automated clinical analysis systems used by
laboratories for cancer and prenatal genetics. The Company markets its
products worldwide and has more than 1600 instruments at 800 customer sites in
over 35 countries. Applied Imaging is a publicly traded company listed on the
Nasdaq Stock Market under the Symbol AICX.
The foregoing statement is a forward-looking statement within the meaning
of Section 27A of the Securities Act and Section 21E of the Securities
Exchange Act. Actual results could differ materially from those projected in
the forward-looking statement as a result of a number of factors including the
failure of the Company to successfully develop or commercialize its prenatal
screening system, lack of regulatory approval, and other such factors as set
forth in the Company's form 10K for the year ended December 31, 1998 as filed
with the Securities and Exchange Commission.
For additional information on Applied Imaging via fax, please dial
1-800-PRO-INFO, (732-544-2850 outside of the U.S.), code AICX.
SOURCE Applied Imaging Corp.
 back to top
CONTACT:
Carl Hull, President of Applied Imaging Corp,
408-450-4302; or General Info, Traci McCarty or Investor Contact,
Janet Nelson, 415-986-1591 both of The Financial Relations Board
for Applied Imaging Corp.
|
